Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MSLE | PRESS-RELEASE | bullish | 6/10 | Satellos received FDA clearance for its IND application for forazapadin in FSHD, a second degenerative muscle disease wi | Sep 24, 2026 |
| SPRC | 6-K | neutral | 3/10 | SciSparc subsidiary NeuroThera announced the publication of three U.S. patent applications covering combinations of its | Sep 24, 2026 |
| HCM | 6-K | bullish | 6/10 | HUTCHMED announced that two positive Phase III studies of savolitinib plus osimertinib in NSCLC were selected for oral p | Sep 24, 2026 |
| LODE | PRESS-RELEASE | neutral | 4/10 | Comstock Inc. announced that its portfolio company Sierra Springs Opportunity Fund (SSOF) has engaged Newmark to advise | Sep 24, 2026 |
| IMRN | 6-K | neutral | 2/10 | Immuron Ltd filed its Appendix 4G and Corporate Governance Statement for the fiscal year ended 30 June 2026 with the ASX | Sep 24, 2026 |
| JAGX | 8-K | bearish | 6/10 | Jaguar Health issued 547,898 common shares to Streeterville Capital in exchange for a $5,049,909.26 reduction in the out | Sep 24, 2026 |
| KYTX | 8-K | bullish | 7/10 | Kyverna Therapeutics reported positive one-year durability data from its registrational KYSA-8 trial of miv-cel in stiff | Sep 24, 2026 |
| MNOV | PRESS-RELEASE | mixed | 7/10 | MediciNova announced completion of the last patient's final visit in the double-blind portion of its Phase 2b/3 COMBAT-A | Sep 24, 2026 |
| GRML | PRESS-RELEASE | bearish | 6/10 | Greenland Mines Ltd raised over $42 million from existing investors via a registered direct offering of common stock and | Sep 24, 2026 |
| GOVX | EFFECT | bearish | 6/10 | GeoVax Labs' S-1 registration statement (File No. 333-298989) became effective on September 23, 2026, allowing the resal | Sep 24, 2026 |
| RADX | EFFECT | bearish | 5/10 | Radiopharm Theranostics Ltd's shelf registration statement on Form F-3 (File No. 333-298912) was declared effective by t | Sep 24, 2026 |
| MPLT | EFFECT | neutral | 4/10 | MapLight Therapeutics' S-1 registration statement (File No. 333-298837) became effective on September 23, 2026. This all | Sep 24, 2026 |
| PMHS | EFFECT | neutral | 3/10 | Polomar Health Services, Inc. (PMHS) received SEC effectiveness on September 23, 2026, for its shelf registration (File | Sep 24, 2026 |
| MESO | 6-K | neutral | 3/10 | Mesoblast received FDA approval to implement a new potency assay (TIBA) for release and stability monitoring of all new | Sep 23, 2026 |
| LTRN | 8-K | neutral | 2/10 | Lantern Pharma filed an 8-K to disclose a live webinar held on September 23, 2026, discussing its Open-Medicine AI multi | Sep 23, 2026 |
| JNJ | COURT-RULING | neutral | 3/10 | A federal district court denied Johnson & Johnson's motion to dismiss a product liability lawsuit alleging that the comp | Sep 23, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced that two positive Phase III studies of savolitinib plus osimertinib in NSCLC were selected for oral p | Sep 23, 2026 |
| ACOG | SC 13G | neutral | 3/10 | Manchester Management Company, LLC and related entities filed a Schedule 13G disclosing a 6.9% passive stake in Alpha Co | Sep 23, 2026 |
| AMPH | CLUSTER | neutral | 3/10 | Two Amphastar insiders, including the CFO and a senior EVP, sold a combined $343K in open-market sales over a one-week w | Sep 23, 2026 |
| ETRA | CLUSTER | bullish | 6/10 | OrbiMed Advisors LLC and Carl L. Gordon, both directors and 10% owners of Electra Therapeutics, made open-market purchas | Sep 23, 2026 |
| GRML | 424B5 | bearish | 6/10 | Greenland Mines Ltd is conducting a registered direct offering of 1,765,420 shares of common stock at $12.00 per share a | Sep 23, 2026 |
| XBIO | 8-K | neutral | 5/10 | Xenetic Biosciences filed an updated investor presentation detailing its proposed reverse merger with Santersus AG, wher | Sep 23, 2026 |
| VKTX | 424B5 | neutral | 4/10 | Viking Therapeutics filed a preliminary prospectus supplement for an offering of convertible senior notes due 2032, with | Sep 23, 2026 |
| VKTX | 424B5 | bearish | 6/10 | Viking Therapeutics filed a preliminary prospectus supplement for an underwritten common stock offering of an undisclose | Sep 23, 2026 |
| GRML | 8-K | bearish | 6/10 | Greenland Mines Ltd. entered into a securities purchase agreement with institutional investors to sell 1,765,420 shares | Sep 23, 2026 |
| TECH | 8-K | bullish | 6/10 | Bio-Techne shareholders voted overwhelmingly to approve the acquisition by Merck KGaA, Darmstadt, Germany, with 121,929, | Sep 23, 2026 |
| IQV | 8-K | neutral | 4/10 | IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings Inc., completed a $2 billion offering of 6.375% senior notes due | Sep 23, 2026 |
| DCOY | 8-K | bearish | 6/10 | Decoy Therapeutics entered into a warrant inducement agreement with Armistice Capital Master Fund Ltd. to immediately ex | Sep 23, 2026 |
| BON | 6-K | bearish | 7/10 | Bon Natural Life reported a net loss of $9.2M for H1 2026 vs net income of $169K in H1 2025, driven by massive credit lo | Sep 23, 2026 |
| ONMDW | 8-K | neutral | 3/10 | OneMedNet Corp filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on September 18, 2026. | Sep 23, 2026 |